AG-348
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pyruvate Kinase Deficiency
Conditions
Pyruvate Kinase Deficiency
Trial Timeline
Jun 26, 2015 → Apr 2, 2025
NCT ID
NCT02476916About AG-348
AG-348 is a phase 2 stage product being developed by Agios Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02476916. Target conditions include Pyruvate Kinase Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04000165 | Phase 1 | Completed |
| NCT03692052 | Phase 2 | Active |
| NCT03559699 | Phase 3 | Completed |
| NCT02476916 | Phase 2 | Completed |
Competing Products
9 competing products in Pyruvate Kinase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 1 | 28 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo + AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Approved | 80 |
| AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| RP-L301 | Rocket Pharmaceuticals | Phase 1 | 25 |
| RP-L301 | Rocket Pharmaceuticals | Phase 2 | 44 |